ArticleBlood advances2019
Primary central nervous system lymphoma: initial features, outcome, and late effects in 75 children and adolescents.
Erratum issuedAbstract read
In one paragraph
Article in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Article
- Central nervous system Burkitt lymphoma: fornix-to-ventricle dissemination.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Anaplastic lymphoma kinase-positive primary CNS anaplastic large cell lymphoma in a pediatric patient: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- Anaplastic large cell lymphoma in children and adolescents.British journal of haematology · 2025Review
- Peripheral T-cell lymphoma-NOS in children and adolescents: a review from the Children's Oncology Group NHL Committee.Blood advances · 2025Review
- The Molecular Landscape of Primary CNS Lymphomas (PCNSLs) in Children and Young Adults.Cancers · 2024Article
- [Clinical study of 15 cases of primary non-immunodeficient central nervous system lymphoma in children].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Article
- Study on primary central nervous system lymphoma in pediatric patients.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2023Review
- Primary central nervous system lymphoma.Nature reviews. Disease primers · 2023Review
- Article
- A genetically distinct pediatric subtype of primary CNS large B-cell lymphoma is associated with favorable clinical outcome.Blood advances · 2022Article
- Bruton's tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review.Frontiers in oncology · 2022Review
- Novel insights into the biomarkers and therapies for primary central nervous system lymphoma.Therapeutic advances in medical oncology · 2022Review
- Primary central nervous system lymphoblastic B cell lymphoma located at cerebellum in a child: A case report and literature review.Pediatric investigation · 2021Article
- Primary central nervous system lymphoma: clinicopathological and genomic insights for therapeutic development.Brain tumor pathology · 2021Review
- Germline Mutations Including the Rare Pathogenic Variant c.3206delC in theChildren (Basel, Switzerland) · 2021Article
- Primary Central Nervous System Lymphomas: A Diagnostic Overview of Key Histomorphologic, Immunophenotypic, and Genetic Features.Diagnostics (Basel, Switzerland) · 2020Review
Corrections and comments
- Erratum issued
Authors and funding
28 authors.
Andishe AttarbaschiDepartment of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria.
Oussama AblaDivision of Hematology and Oncology, Department of Pediatrics, Hospital for Sick Children, Toronto, ON, Canada.
Leila RoncerayDepartment of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria.
Shweta BansilDivision of Pediatric Hematology and Oncology, Department of Pediatrics, Weill Cornell Medical College, New York, NY.
Simon BomkenNorthern Institute for Cancer Research, Newcastle University, Newcastle, United Kingdom.
Birgit BurkhardtDepartment of Pediatric Hematology and Oncology, University of Münster, Münster, Germany.
Francecso CeppiPediatric Hematology-Oncology Research Laboratory and Pediatric Hematology-Oncology Unit, Division of Pediatrics, Department Woman-Mother-Child, Lausanne University Hospital, Lausanne, Switzerland.
Alan K S ChiangDepartment of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong.
Hema DaveCenter for Cancer and Blood Disorders, Children's National Medical Center, The George Washington University, Washington, DC.
Alina FedorovaBelarusian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Belarus.
Michael HenryCenter for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ.
Janez JazbecDivision of Pediatrics, Hematology, and Oncology, University Medical Center Ljubljana, Ljubljana, Slovenia.
Edita KabickovaDepartment of Pediatric Hematology and Oncology, Charles University and University Hospital Motol, Prague, Czech Republic.
Rishi S KotechaTelethon Kids Cancer Centre, Telethon Kids Institute, University of Western Australia, Perth, WA, Australia.
Jelena LazicDepartment of Pediatric Hematology and Oncology, University Children's Hospital, School of Medicine, University of Belgrade, Belgrade, Serbia.
Jan LoeffenPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Natalia MiakovaDepartment of Pediatric Hematology and Oncology, Federal Center for Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.
Tomoo OsumiChildren's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
Marta PillonDepartment of Pediatric Hematology and Oncology, University of Padova, Padova, Italy.
Apostolos PourtsidisDepartment of Oncology, "P. & A. Kyriakou" Children's Hospital, Athens, Greece.
Charlotte RigaudDepartment of Pediatric and Adolescent Oncology, Gustave-Roussy Cancer Center, Paris-Sacaly University, Villejuif, France.
Gevorg TamamyanDepartment of Pediatric Oncology and Hematology, Yerevan State Medical University, and Pediatric Cancer and Blood Disorders Center of Armenia, Yerevan, Armenia.
Sneha TandonDivision of Hematology and Oncology, Department of Pediatrics, Hospital for Sick Children, Toronto, ON, Canada.
Anne UyttebroeckDepartment of Pediatric Hematology and Oncology, University Hospital Leuven, Leuven, Belgium.
Jamie Verdu-AmorosDepartment of Pediatric Hematology and Oncology, University Hospital of Valencia, Valencia, Spain.
Wilhelm WoessmannDepartment of Pediatric Hematology and Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; and.
Grazyna WrobelBone Marrow Transplantation and Pediatric Hematology and Oncology, Wroclaw Medical University, Wroclaw, Poland.
Lisa Giulino-RothDivision of Pediatric Hematology and Oncology, Department of Pediatrics, Weill Cornell Medical College, New York, NY.
Funding
Rational Translation of EZH2 Targeted Therapy in Germinal Center B-cell LymphomaK08CA219473 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI ROTH, LISA GIULINO · 2017 to 2020
$684kNCI NIH HHS K08 CA219473
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.